🇺🇸 FDA
Patent

US 11266726

Compositions and methods for the treatment of HER2-expressing solid tumors

granted A61KA61K2039/5256A61K40/19

Quick answer

US patent 11266726 (Compositions and methods for the treatment of HER2-expressing solid tumors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/5256, A61K40/19, A61K40/24, A61K40/30